EIF2AK2 anticorps (N-Term)

N° du produit ABIN360663

Détail du produit anti-EIF2AK2 anticorps

Antigène: EIF2AK2 (Eukaryotic Translation Initiation Factor 2-alpha Kinase 2 (EIF2AK2))

Épitope: N-Term

Reactivité: Humain, Souris

Hôte: Lapin

Clonalité: Polyclonal

Conjugué: Cet anticorp EIF2AK2 est non-conjugé

Application: Western Blotting (WB), Immunohistochemistry (Paraffin-embedded Sections) (IHC (p)), Enzyme Immunoassay (EIA)

Specificité: This antibody reacts to PRKR.

Purification: Prepared by Saturated Ammonium Sulfate (SAS) precipitation followed by dialysis against PBS

Immunogène: This antibody is generated from rabbits immunized with a KLH conjugated synthetic peptide selected from the N-terminal region of human PRKR.

Isotype: Ig Fraction

Information d'application

Indications d'application: ELISA: 1/1,000. Western blotting: 1/100 - 1/500. Immunohistochemistry: 1/50 - 1/100. Flow cytometry.

Restrictions: For Research Use only

Stockage

Format: Liquid

Concentration: 0.25 mg/mL

Buffer: PBS with 0.09 % (W/V) sodium azide

Agent conservateur: Sodium azide

Précaution d'utilisation: This product contains sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Conseil sur la manipulation: Avoid repeated freezing and thawing.

Stock: 4 °C/-20 °C

Stockage commentaire: Store the antibody undiluted at 2-8 °C for one month or (in aliquots) at-20 °C for longer.

Détails sur EIF2AK2

Antigène: EIF2AK2 (Eukaryotic Translation Initiation Factor 2-alpha Kinase 2 (EIF2AK2))

Autre désignation: EIF2AK2 / PKR (EIF2AK2 Produits)

Synonymes: anticorps PKR, anticorps pkr, anticorps EIF2AK2, anticorps DKFZp469K1934, anticorps EIF2AK1, anticorps PRKR, anticorps 2310047A08Rik, anticorps 4732414G15Rik, anticorps AI467567, anticorps AI747578, anticorps Pkr, anticorps Prkr, anticorps Tik, anticorps eukaryotic translation initiation factor 2 alpha kinase 2, anticorps eukaryotic translation initiation factor 2-alpha kinase 2, anticorps EIF2AK2, anticorps eif2ak2, anticorps Eif2ak2

Sujet: Interferon-induced, double-stranded RNA-activated protein kinase (PRKR) is a serine-threonine kinase. Activation by dsRNAs leads to autophosphorylation of PRKR and allows the kinase to phosphorylate its natural substrate, the alpha subunit of eukaryotic protein synthesis initiation factor-2 (EIF2-alpha), leading to the inhibition of protein synthesis. Human gamma-interferon (IFNG) mRNA exploits localized activation of PRKR in the cell to regulate its own translation. IFNG mRNA activates PRKR through a pseudoknot in its 5-prime untranslated region. The HCV envelope protein E2 contains a sequence identical with phosphorylation sites of the interferon-inducible protein kinase PRKR and the translation initiation factor EIF2-alpha, a target of PRKR. E2 inhibits the kinase activity of PRKR and blocks its inhibitory effect on protein synthesis and cell growth, which provides one mechanism by which HCV may circumvent the antiviral effect of interferon. PRKR, which is involved in TLR signaling and mediates apoptosis in fibroblasts in response to viral infection and inflammatory cytokines, also activates IKK and NFKB, thereby suppressing apoptosis. Apoptosis induced by live pathogenic gram-positive and gram-negative bacteria requirs both TLR4 and PRKR, possibly representing a major mechanism for pathogenic bacteria that use specific virulence factors to avoid detection and destruction by the innate immune system. Roles for PRKR activation in Huntington disease and Fanconi anemia have also been suggested.Synonyms: Eukaryotic translation initiation factor 2-alpha kinase 2, Interferon-induced double-stranded RNA-activated protein kinase, PRKR, Protein kinase RNA-activated, eIF-2A protein kinase 2, p68 kinase

ID gène: 5610

NCBI Accession: NP_001129123

UniProt: P19525

Pathways: Réparation de l'ADN, ER-Nucleus Signaling, Hepatitis C